Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia

Keyphrases

• Metformin 100%
• Tyrosine Kinase Inhibitor 100%
• Chronic Myeloid Leukemia 100%
• Inhibitor Response 100%
• Complete Cytogenetic Response 83%
• Tyrosine Kinase Inhibitor Therapy 83%
• Cell Viability 16%
• MTORC1 Signaling 16%
• Induced Apoptosis 16%
• Signaling Pathway 16%
• Newly Diagnosed 16%
• First-line Therapy 16%
• Patients with Diabetes 16%
• Academic Medical Centers 16%
• Overall Survival 16%
• Leukemia Cell Lines 16%
• Myeloid Leukemia Cells 16%
• Baseline Characteristics 16%
• Long-term Survival 16%
• Imatinib Resistance 16%
• Glucose-lowering Drugs 16%
• Metformin Use 16%
• Chronic Myelogenous Leukemia Cells 16%
• Oral Tyrosine Kinase Inhibitors 16%
• Tyrosine Kinase Inhibitor Treatment 16%

Medicine and Dentistry

• Glycon 100%
• Chronic Myelogenous Leukemia 100%
• Tyrosine-Kinase Inhibitor 100%
• Mental Capacity 25%
• Observational Study 12%
• Cell Signaling Pathway 12%
• Programmed Cell Death 12%
• Myeloid Leukemia 12%
• Stem Cell 12%
• Patient with Diabetes 12%
• Imatinib 12%
• Overall Survival 12%
• Long Term Survival 12%
• Cell Viability 12%
• Chronic Myeloid Leukemia Cell Line 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Metformin 100%
• Protein Tyrosine Kinase Inhibitor 100%
• Chronic Myeloid Leukemia 100%
• Preclinical Study 12%
• Observational Study 12%
• Cell Viability 12%
• Overall Survival 12%
• Long Term Survival 12%
• Imatinib 12%
• Myeloid Leukemia 12%